MAIA Biotechnology, Inc. (MAIA)
MAIA Biotechnology is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer.
THIO, our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies.
THIO is being developed as a second- or later line of treatment for Non-Small Cell Lung Cancer (NSCLC) for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
THIO will enter Phase 2 human trials in Australia and Europe in the first half of 2022. Based on the clinical data generated by this trial, in late 2024 we plan to seek an accelerated approval of THIO in the United States for the treatment of patients with advanced NSCLC, but even if granted, accelerated approval status does not guarantee an accelerated review or marketing approval by the FDA.
In addition, we plan to start activities for a clinical trial of THIO in patients with advanced colorectal cancer in the first quarter of 2023.
|IPO Date||Jul 28, 2022|
444 West Lake Street, Suite 1700
Chicago, IL 60606
|Phone||312 416 8592|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Dr. Vlad Vitoc M.B.A., M.D.||Co-Founder, President, Chief Executive Officer and Chairman of Directors|
|Joseph F. McGuire||Chief Financial Officer|
|Dr. Mihail Obrocea M.D.||Chief Medical Officer and Head of Development|
|Dr. Sergei M. Gryaznov Ph.D.||Chief Scientific Officer|